XML 33 R22.htm IDEA: XBRL DOCUMENT v3.23.1
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)
 12 Months Ended
Dec. 31, 2022
Accounting Policies [Abstract]  
SCHEDULE OF UNREALIZED GAINS AND LOSSES

 

   Initial Book Value   Cumulative
Gross
Unrealized
Gains		   Cumulative
Gross
Unrealized
Losses		   Fair
Value		 
December 31, 2022                    
                     
Investment in GMP Bio (equity securities)  $22,640,519   $    -   $    -   $22,640,519 
Total  $22,640,519   $-   $-   $22,640,519 
SUMMARY OF CHANGES IN FAIR VALUE OF LONG-TERM INVESTMENT IN EQUITY SECURITIES

 

   December 31, 2022
Fair Value		 
Balance at January 1, 2022  $- 
Contribution at cost basis   5,689,042 
Gain on derecognition of non-financial asset   16,951,477 
Change in fair value   - 
      
Balance at December, 2022  $22,640,519 
SUMMARY OF CHANGES IN FAIR VALUE OF DERIVATIVE LIABILITIES

The table below sets forth a summary of the changes in the fair value of the Company’s derivative liabilities classified as Level 3 as of December 31, 2022 and 2021:

 

   December 31, 2022
Conversion Feature		   December 31, 2021
Conversion Feature		 
Balance at beginning of the year ended  $340,290   $777,024 
New derivative liability   -    - 
Reclassification to additional paid in capital from conversion of debt to common stock   -    (144,585)
Change in fair value   (142,150)   (292,149)
           
Balance at the end of the year ended  $198,140   $340,290 
SUMMARY OF ESTIMATE FAIR VALUE OF DERIVATIVE LIABILITIES

 

   December 31, 2022   December 31, 2021 
Risk free interest   0.17% - 4.0%  0.3%
Market price of share  $ 0.05 - 0.23   $0.17 
Life of instrument in years   0.01 - 0.33    0.31 
Volatility   99.80% - 116.51 %    140%
Dividend yield   0%   0%
SCHEDULE OF BASIC AND DILUTED WEIGHTED AVERAGE COMMON STOCK OUTSTANDING

The table below sets forth a reconciliation of the basic weighted average common stock outstanding to the diluted weighted average common stock outstanding of the Company as of December 31, 2022:

 

   December 31, 2022 
Basic weighted average common stock outstanding   384,075,369 
Add: Dilutive common stock equivalents     
Stock options outstanding   2,606,054 
Warrants outstanding   68,681 
Convertible debt, convertible into common stock   70,549,786 
      
Diluted weighted average common stock outstanding   457,299,890